Clinical utility of polygenic risk scores: a critical 2023 appraisal
In conclusion, the benefit to individual patients or the health care system in general of PRS-based extensions of existing diagnostic or treatment regimens is still difficult to judge.
Source: Journal of Community Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Bipolar | Breast Cancer | Cancer | Cancer & Oncology | Diabetes | Endocrinology | Environmental Health | Genetics | Health Management | Mania | Parkinson's Disease | Prostate Cancer | Schizophrenia | Study